Originalartikel | erschienen - Druck | peer reviewed | Open Access
Downregulation of interleukin 6 signaling might reduce the risk of periodontitis: a drug target Mendelian randomization study.
Frontiers in Immunology
2023 / Juni
;
14:
1160148 -
Bibliometrische Indikatoren
Impact Factor = 5,7
Zitierhäufigkeit nach WOS = 17
DOI = 10.3389/fimmu.2023.1160148
PubMed-ID = 37342352
Autoren
Nolde M*, Alayash Z, Reckelkamm S, Kocher T1, Ehmke B, Holtfreter B1, Baurecht H, Georgakis M, Baumeister SE
Beteiligte Einrichtungen
Abstract
Interleukin 6 (IL-6) is considered to play a role in the dysbiotic host response in the development of periodontitis. While the inhibition of the IL-6 receptor using monoclonal antibodies is a well-established therapy for some diseases, so far, its potential benefit in patients with periodontitis has not been examined. We tested the association of genetically proxied downregulation of IL-6 signaling with periodontitis to explore whether downregulation of IL-6 signaling could represent a viable treatment target for periodontitis.
Veröffentlicht in
Frontiers in Immunology
Jahr | 2023 |
Monat/Hj. | Juni |
Impact Factor (2023) | 5,7 |
Volume | 14 |
Issue | |
Seiten | 1160148 - |
Open Access | ja |
Peer reviewed | ja |
Artikelart | Originalartikel |
Artikelstatus | erschienen - Druck |
DOI | 10.3389/fimmu.2023.1160148 |
PubMed-ID | 37342352 |
Allgemeine Daten zur Fachzeitschrift
Kurzbezeichnung: FRONT IMMUNOL
ISSN: 1664-3224
eISSN: 1664-3224
Land: SWITZERLAND
Sprache: English
Kategorie(n):
Impact Factor Entwicklung
ISSN: 1664-3224
eISSN: 1664-3224
Land: SWITZERLAND
Sprache: English
Kategorie(n):
- IMMUNOLOGY
Impact Factor Entwicklung
Jahr | Impact Factor |
---|---|
2015 | 5,695 |
2016 | 6,429 |
2017 | 5,511 |
2018 | 4,716 |
2019 | 5,085 |
2020 | 7,561 |
2021 | 8,786 |
2022 | 7,3 |
2023 | 5,7 |
2024 | 5,9 |
Themenschwerpunkte
FAQs | Impressum | Datenschutz